Skip to main content

Table 3 Distribution of SNPs in IL-27 among NMIBC and MIBC patients

From: Polymorphisms and plasma levels of IL-27: impact on genetic susceptibility and clinical outcome of bladder cancer

  

rs153109

rs17855750

Model

Genotype

NMIBC

MIBC

OR (95 % CI)a

P valuea

Genotype

NMIBC

MIBC

OR (95 % CI)a

P valuea

N = 176 (%)

N = 156 (%)

N = 176 (%)

N = 156 (%)

Codominant

AA

66 (37.5 %)

61 (39.1 %)

1.00 (reference)

0.99

TT

149 (84.7 %)

126 (80.8 %)

1.00 (reference)

0.076

AG

87 (49.4 %)

73 (46.8 %)

1.04 (0.60–1.81)

TG

26 (14.8 %)

27 (17.3 %)

0.53 (0.26–1.09)

GG

23 (13.1 %)

22 (14.1 %)

1.02 (0.46–2.27)

GG

1 (0.6 %)

3 (1.9 %)

0.15 (0.01–1.84)

Dominant

AA

66 (37.5 %)

61 (39.1 %)

1.00 (reference)

0.88

TT

149 (84.7 %)

126 (80.8 %)

1.00 (reference)

0.042

AG/GG

110 (62.5 %)

95 (60.9 %)

1.04 (0.62–1.75)

TG/GG

27 (15.3 %)

30 (19.2 %)

2.04 (1.02–4.17)

Recessive

AA/AG

153 (86.9 %)

134 (85.9 %)

1.00 (reference)

0.99

TT/TG

175 (99.4 %)

153 (98.1 %)

1.00 (reference)

0.14

GG

23 (13.1 %)

22 (14.1 %)

1.00 (0.48–2.09)

GG

1 (0.6 %)

3 (1.9 %)

0.17 (0.01–2.07)

Overdominant

AA/GG

89 (50.6 %)

83 (53.2 %)

1.00 (reference)

0.88

TT/GG

150 (85.2 %)

129 (82.7 %)

1.00 (reference)

0.1

AG

87 (49.4 %)

73 (46.8 %)

1.04 (0.63–1.73)

TG

26 (14.8 %)

27 (17.3 %)

0.55 (0.27–1.13)

 

Allele

         
 

A

219 (62.2)

195 (62.5)

0.99 (0.72–1.35)

0.94

T

324 (92.0)

279 (89.4)

1.37 (0.81–2.32)

0.28

 

G

133 (37.8)

117 (37.5)

G

28 (8.0)

33 (10.6)

  1. N corresponds to the number of individuals
  2. aAdjusted by age, sex and smoking status
  3. Boldfaced values indicate a significant difference at the 5 % level
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us